|
US2005260236A1
|
|
Direct compression polymer tablet core
|
|
WO02100395A1
|
|
Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
|
|
WO02085380A1
|
|
Method for treating gout and reducing serum uric acid
|
|
WO02085383A1
|
|
Method for reducing copper levels and treating copper toxicosis
|
|
WO02085378A1
|
|
Low salt forms of polyallylamine
|
|
WO02085382A1
|
|
Methods of treating syndrome x with aliphatic polyamines
|
|
WO02085379A1
|
|
Method for improving vascular access in patients with vascular shunts
|
|
ZA200202772B
|
|
Direct compression polymer tablet core.
|
|
EP1815861A2
|
|
Ionene polymers and their use as antimicrobial agents
|
|
ZA200109290B
|
|
Anionic polymers as toxin binders and antibacterial agents.
|
|
US2001051660A1
|
|
Method for reducing oxalate
|
|
AU7545001A
|
|
Bismuth compounds for the treatment and prevention of mucositis
|
|
AU2979901A
|
|
Ionic polymers as anti-infective agents
|
|
AU2293101A
|
|
Method for making hbed
|
|
CA2314494A1
|
|
Anionic polymers as species specific antibacterial agents
|
|
AU5916700A
|
|
Combination chemotherapy
|
|
US6290947B1
|
|
Ionic polymers as toxin-binding agents
|
|
US6482402B1
|
|
Antimicrobial compositions and methods
|
|
US6290946B1
|
|
Anionic polymers as toxin binders and antibacterial agents
|
|
US6270755B1
|
|
Anionic polymers as toxin binders
|
